Basel Medical

BMGL

Market cap $11.4M

LOS ANGELES, April 23, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Basel Medical Group Ltd (“Basel” or “the Company”) (NASDAQ: BMGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Basel Medical Group Ltd. (NASDAQ: BMGL) resulting from allegations that Basel Medical may have issued materially misleading business information to the investing public. So what: If you purchased Basel Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Basel Medical Group Ltd. (NASDAQ: BMGL) resulting from allegations that Basel Medical may have issued materially misleading business information to the investing public. So what: If you purchased Basel Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency.

Singapore, March 24, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that based on the Company's amended annual report on Form 20-F for the fiscal year of 2025, which was filed with the SEC on March 13, 2026, Nasdaq Staff has now determined that the Company has complied with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Periodic Filing Rule”). Accordingly, the prior deficiency relating to the Periodic Filing Rule has now been resolved.

Singapore, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that it has received notification from Nasdaq that based on the closing bid price of the Company's shares for the last 30 consecutive business days, the Company no longer meets the requirements under Nasdaq's Listing Rules (the “Rules”) for listed securities to maintain a minimum bid price of $1 per share.

Singapore, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that it has received notification from Nasdaq that the Company's annual report on Form 20-F for the fiscal year ended June 30, 2025 was incomplete and that the Company is delinquent in its filing obligations. This was because such report failed to include an opinion from the Company's auditor, NLA DFK Assurance PAC, on the Company's financial statements.

Singapore, July 17, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced that it is putting on hold on the acquisition of BTC digital asset. After thorough discussions, Basel and the consortium of Bitcoin (BTC) holders have mutually agreed to pause the acquisition of digital asset. This decision reflects the ongoing regulatory review of digital assets by US authorities and the current lack of clarity on how forthcoming policies may impact the transaction.

Singapore, June 26, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”), today announced that Cathay Securities, Inc., as the representative of the several underwriters of the Company's initial public offering, has granted its consent on June 23, 2025 to the lock-up provision in the underwriting agreement dated February 24, 2025, permitting (i) a public offering or private placement of new securities of the Company, and (ii) the filing with the U.S. Securities and Exchange Commission of a registration statement under the Securities Act of 1933 in relation to such offering or placement, prior to the expiration of the lock-up period which was due to expire six months from the closing of the initial public offering.

Singapore, May 29, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today reaffirmed the strength of its underlying financial performance and strategic outlook, despite recent volatility in its share price.

Singapore, May 22, 2025 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL or the “Company”), today announced that it has entered into a purchase agreement with a consortium of Bitcoin (BTC) holders for the purchase by the Company of up to 10,000 BTC (with current market value of approximately US$1.0 billion) by issuing of its ordinary shares.